Linear Health Sciences Receives Vicient Innovative Technology Contract for Orchid SRV IV Safety Device

OKLAHOMA CITY–(BUSINESS WIRE). Awarded based on the recommendation for the Orchid SRV by hospital professionals serving on one of the Vicient-led panels, the contract represents unique qualities for Vicient members with the potential to bring improvements to the healthcare industry.

Innovative Technology contracts are recommended after review and interaction with products submitted through Vicient’s Innovative Technology program. Councils led by Vicient identify technologies that have the potential to improve clinical care, patient safety, healthcare worker safety, or improve the business operations of healthcare organizations.

The Orchid SRV is a sterile, single-use connector for needle-free access that, when activated, makes return-to-treatment quick, easy, and clean while enhancing the patient and physician experience. Clinical simulation testing of 360 orchid SRVs showed that the device prevented IV displacement by 91.9 percent in all test groups. The device is placed between the existing IV extension set and a general IV tubing connector intended for the delivery of fluids to and from an IV catheter.

According to a study published in JAVA, 95 percent of 1,561 US clinicians surveyed agreed that IV dislocations continue to pose safety risks for patients and hospitals. In fact, reports have shown this from the 342 million peripheral IVs in the US each year1up to 10 percent can become detached2that cost more than $2 billion annually3. Dislocation is most commonly caused when the patient is confused or removes the catheter, loose bandage or tape, or tubing tangled in bedding.

When tension (up to 3.25 lbs.) is applied to the IV tubing, the Orchid SRV separates and seals both sides of the IV tubing, creating a sterile barrier. The clinician then restores the line by simply removing the severed halves and replacing them with a new, prepackaged, sterile valve.

“Receiving an order for innovative technology from Vicient demonstrates that our platform of breakaway safety release valve technologies is an important tool in improving patient safety and improving clinical care for the estimated 90 percent of hospitalized patients who require treatment with IV therapies said Dan Clark, Co-Founder, President and COO of Linear Health Sciences. “We anticipate that our current and future pipeline of platform technology-based products will help clinicians provide better and safer care to patients in all applications at risk of medical tubing dislodgement.”

“A product earns this type of contract when it has a unique quality that sets it apart from other products on the market,” said Kelly Flaharty, Vicient’s senior director of contract services. “Our Member Council has determined that Linear Health Science’s Orchid SRV meets this standard and recognizes its potential to improve quality outcomes.”

Vicient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated healthcare networks and non-acute healthcare providers, and represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vicient works with Member-led councils and task forces come together to evaluate products for their potential to bring true innovation to healthcare. Vicient may award a contract to products deemed worthy of the Innovative Technology designation outside of the bidding period.

About linear health sciences

Linear Health Sciences is a medical technology company that developed proprietary breakaway safety valve technology to improve the use of medical tubing in hospitals. The platform technology is designed to increase patient, caregiver and healthcare facility safety and satisfaction while dramatically reducing costs. The Company’s initial products include the Orchid SRV for use in IV catheter therapy and the Orchid SRV Type D device for use in surgery/wounds, nephrostomy and abscess drainage. Visit for more information.


1 iData Research Report

2 “The Peripheral Intravenous Catheter Journey: A Prospective Cohort Study of 1000 Patients.” panel presentation

3 Helmet al. “Accepted but Unacceptable: Peripheral IV Catheter Failure” J Infus Nurs May-Jun 2015;38(3):189-203. doi: 10.1097/NAN.00000000000000100


Leave a Reply

Your email address will not be published. Required fields are marked *